Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Schizophrenia Proteome Data High Resolution Method

ABSTRACT: PTM-tolerant quantitative proteome analysis of plasma collected from schizophrenia patients and nonspychiatric healthy controls.

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: David Gonzalez

PROVIDER: MSV000086977 | MassIVE | Tue Mar 02 15:36:00 GMT 2021

SECONDARY ACCESSION(S): PXD024474

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Publications

Induction of a macrophage-suppressive lymphokine by soluble cryptococcal antigens and its association with models of immunologic tolerance.

Blackstock R R McCormack J M JM Hall N K NK

Infection and immunity 19870101 1

Soluble extracts of Cryptococcus neoformans were examined for their ability to induce a macrophage-regulatory T-suppressor cell known to appear in the spleens of mice infected with cryptococci. Suppressor cells were induced by injection of extracts of encapsulated or thinly encapsulated strains of cryptococci. Dose-response analysis showed that as little as 25 micrograms of soluble capsular polysaccharide antigen could induce significant suppressor cell activity, with maximum suppression occurri ...[more]

PMID: 2947863

Similar Datasets

Plasma exosomes lncRNA-miRNA-mRNA network construction and its diagnostic efficacy identification in first-episode schizophrenia

Project description:This study examined the miRNA expression level in exosomal derived from the plasma of first episode schizophrenia (FOS) patients and Healthy controls (HC), and explored the the potential of exosomes as biomarkers for schizophrenia. This study examined the lncRNA expression level in exosomal derived from the plasma of first episode schizophrenia (FOS) patients and Healthy controls (HC), and explored the the potential of exosomes as biomarkers for schizophrenia. This study examined the mRNA expression level in exosomal derived from the plasma of first episode schizophrenia (FOS) patients and Healthy controls (HC), and explored the the potential of exosomes as biomarkers for schizophrenia.

2023-08-30 | GSE228881 | GEO

The Multiomics Landscape of Plasma Exosomes in First-Episode Drug-Naïve of Schizophrenia

Project description:This research project aims to explore the multiomics landscape of plasma exosomes in patients with schizophrenia. Our study involves 10 first-episode drug-naïve schizophrenia patients and 10 healthy controls. By comparing the exosomes derived from these two groups, we hope to uncover biomarkers associated with schizophrenia and potential pathogenic mechanisms. The project seeks to provide new insights for the early diagnosis and intervention of schizophrenia.

2025-08-25 | PXD061889 | Pride

Serum metabolomics in schizophrenia

Project description:Twenty-nine patients with schizophrenia and 30 healthy controls were enrolled.

2024-07-04 | MSV000095242 | MassIVE

Serum proteomics in schizophrenia

Project description:Twenty-nine patients with schizophrenia and 30 healthy controls were enrolled.

2024-07-03 | MSV000095241 | MassIVE

miRNA expression in blood of 15 schizophrenia patients and 15 healthy controls

Project description:The study profiles genome-wide miRNA expression in blood from 15 early-onset SZ (EOS) cases and 15 healthy controls. A total of 1070 miRNAs were detected by the microarrays in our samples. We profiles miRNA expression in 15 schizophrenia samples and 15 healthy controls to explore the alteration of miRNAs in schizophrenia.

2014-12-02 | GSE54578 | GEO

Gene expression data from DLPFC of schizophrenia patients

Project description:We analyzed gene co-expression modules (clusters of genes with highly correlated expression) in the dorsolateral prefrontal cortex (DLPFC) of postmortem brains from patients with schizophrenia and healthy controls. We aimed to identify the co-expressed modules that reflect the genetic differences between clozapine-treated and non-clozapine-treated patients with schizophrenia as a proxy of TRS.

2025-10-01 | GSE244782 | GEO

High Frequency of CNV Mutations in Combined Schizophrenia and Epilepsy

Project description:Agilent custom designed array comparative genomic hybridization (CGH) was performed on 235 samples with a dual diagnosis of schizophrenia and epilepsy and 80 samples with a dual diagnosis of bipolar and epilpsy. ArrayCGH on 191 psychiatric screened controls was also performed. A common male reference was used for all samples and controls. Samples and controls were obtained from the NIMH cell line repositories. 235 samples with a dual diagnosis of schizophrenia and epilepsy, 80 samples with a dual diagnosis of bipolar and epilepsy, and 191 psychiatric screened controls

2010-12-31 | E-GEOD-23703 | biostudies-arrayexpress

A Co-Culture Model of Dopaminergic and Glutamatergic Neurons Derived from Patients with Idiopathic Schizophrenia reveals a Hypodopaminergic Phenotype

Project description:To identify morphological and functional phenotypes relevant for SCZ, we generated iPSC-derived dopaminergic neurons from three healthy controls and four patient with schizophrenia. We then performed gene expression profiling analysis using data obtained from RNA-seq of four schizophrenia patients and three controls to determine significantly deregulated genes in schizophrenia dopaminergic neurons.

2024-08-27 | GSE275064 | GEO

Gene expression profiles of patients with schizophrenia, bipolar disorder and healthy controls

Project description:Schizophrenia (SZ) and bipolar disorder (BD) are severe psychiatric conditions, with a lifetime prevalence of about 1%. Both disorders have a neurodevelopment component, with onset of symptoms occurring most frequently during late adolescence or early adulthood. Genetic findings indicate the existence of an overlap in genetic susceptibility across the disorders. These gene expression profiles were used to identify the molecular mechanisms that differentiate SZ and BP from healthy controls but also that distinguish both from healthy individuals. They were also used to expand an analysis from an experiment that searched molecular alterations in human induced pluripotent stem cells derived from fibroblasts from control subject and individual with schizophrenia and further differentiated to neuron to identify genes relevant for the development of schizophrenia (GSE62105). Brain tissue (frontal cortex) from 30 healthy controls, 29 bipolar disorder patients and 29 schizophrenia patients were analyzed. The reference is an in-house pool of RNA extracted from 15 human cell lines.

2014-10-11 | E-GEOD-62191 | biostudies-arrayexpress

Utilising Psych Arrays for the identification of CNVs and SNPs from Schizophrenia cases and controls from South-India.

Project description:Genotyping data on 192 schizophrenia cases and 181 healthy controls was generated using Psych Array V 1.3 Aim: To identify CNVs and SNPs associated with increased risk of schizophrenia

2024-01-16 | GSE242813 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data